Peripheral Arterial Insufficiency

Three researchers in the U.S. have each been awarded a grant from the Friedreich's Ataxia Research Alliance (FARA) to explore new strategies for treating Friedreich's ataxia (FA), the nonprofit announced on its scientific news page. The newest FARA grant recipients are three professors from across the U.S. — Stephanie Cherqui, PhD, from the University of California, San Diego, Mark Payne, MD, from the Indiana University School of Medicine, and Shannon Boye, PhD, from the University of Florida. Their work is focused on stem cells, and on finding therapies for heart and eye problems. "FARA's mission is to marshal and focus the resources and relationships needed to cure FA," the organization states on its website, adding that its work focuses on "aligning scientists, patients, clinicians, government agencies, pharmaceutical companies and other organizations dedicated to curing FA and related diseases." Recommended Reading

atrial fibrillation treatment :: Article Creator Could Untreated AFib Raise The Risk Of Memory Decline? For people with untreated atrial fibrillation (AFib), the risk of developing mild cognitive impairment, and perhaps dementia, appears to be significantly higher, according to a new research letter. The study found that people whose AFib is being successfully treated are at no higher risk of cognitive issues. AFib can result in tiny, imperceptible blood clots, degrading the brain's function over time. For people with comorbidities along with untreated AFib, the risk of mild cognitive impairment and dementia is even greater. A large study found that there is an association between untreated atrial fibrillation and eventual mild cognitive impairment (MCI) that may lead to dementia. Researchers found that people with atrial fibrillation (AFib) were at a 45% higher risk of MCI than those without AFib, or with AFib that was being treat

tavr procedure :: Article Creator Combining TAVR, LAA Closure In Same Procedure Safe, Trial Says SAN FRANCISCO -- Left atrial appendage occlusion (LAAO) at the time of transcatheter aortic valve replacement (TAVR) appeared as safe as TAVR alone, the WATCH-TAVR trial showed. For patients with severe aortic stenosis and atrial fibrillation (AF or Afib), the combined approach met non-inferiority to TAVR plus medical therapy for the primary composite endpoint of all-cause mortality, stroke, and major bleeding at 2 years (22.7 vs 27.3 events per 100 patient-years, P<0.001 for non-inferiority). While the hazard ratio for that combined endpoint favored TAVR plus LAAO (HR 0.86, 95% CI 0.60-1.22), it was not significantly superior (P=0.40), reported Samir Kapadia, MD, of the Cleveland Clinic, at the Transcatheter Cardiovascular Therapeutics (TCT) meeting and online in Circulation. Some 20% of TAVR patients subsequently get a Watchman device for

L-r: Sahil Parikh, Peter Schneider and William A Gray Data from a patient-level meta-analysis—a factor in the US Food and Drug Administration's (FDA) recent change of position on the use of paclitaxel-coated devices to treat peripheral arterial disease (PAD)—have been made public for the first time at TCT 2023 (23–26 October, San Francisco, USA). The analysis led investigators to conclude that there is no association between mortality risk and paclitaxel-coated device exposure or dose, and should provide reassurance to patients, physicians and regulators on the safety of paclitaxel-coated devices, they say. The release of the data, which has also been published today in The Lancet, draws a line in the sand over the question of the safety of paclitaxel, which is used in peripheral interventions to prevent restenosis, after data &nbsp;from a summary-level meta-analysis put forward in 2018 pointed to an increased risk of death at two and five years following the use of pacl

Abdominal aortic aneurysm (AAA) is enlargement of the abdominal portion of the body's largest artery, the aorta. Aneurysms grow slowly over time, and with small ones there are often no symptoms at all. However, larger aneurysms and rapidly expanding aneurysms can cause symptoms, and even rupture (burst) or dissect (tear). AAA rupture and dissection are life-threatening situations that can cause severe low blood pressure, dizziness, rapid heart rate, and sudden, severe abdominal pain. Read on to learn more about abdominal aortic aneurysm, its symptoms, diagnosis, and treatment options. Zero Creatives / Getty Images Causes of Abdominal Aortic Aneurysm Abdominal aortic aneurysms are caused by weakening of the aortic wall, causing bulging and enlargement in the affected area. Atherosclerosis, or build-up of plaque in the blood vessel wall, is commonly seen in aneurysms. Other risk factors for abdominal aortic aneurysm include: Smoking- about

Specialty Adblock test (Why?)

A heart attack, also called a myocardial infarction (MI), is when the heart muscle is suddenly deprived of oxygen, usually due to a blockage. If oxygenation is not restored quickly, the heart muscle can die. Heart attacks are typically a result of coronary artery disease (CAD). More than 800,000 people in the United States have a heart attack yearly. Understanding what can contribute to coronary artery disease can help prevent a heart attack. Ahmani Vidal / Getty Images While it is possible to have mild or even no symptoms with a heart attack (silent heart attack), most people who have heart attacks experience some of the following: Pain or heaviness in the chest, usually in the center of the left side of the chest Pain or discomfort in one or both arms, upper back, shoulders, neck, or jaw Difficulty breathing at rest or with minimal physical exertion Sudden sweating without any reason Feeling excessively tired without good reason Nausea or